Jobs
Photo test in kansas
They companies “top-line results from a Phase 3 randomized, controlled trial evaluating the efficacy and safety of a 30-µg booster dose of the Pfizer-BioNTech Covid-19 vaccine in more than 10,000 individuals 16 years of age and older.”
The companies plan to give the data to the FDA, the European Medicines Agency and other regulators worldwide.
At last check shares of Pfizer, the New York health-care group, were little changed at $42.83 while BioNTech shares dropped 4.3% to $274.13
hello
This story was originally published October 22, 2021 10:06 AM.
